Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Choose One, Not Both: Why Balanced Biopharma Funds Stumble

This article was originally published in Start Up

Executive Summary

By the end of this year, three major US venture firms---JP Morgan Partners, the American affiliate of Apax, and MPM Capital--will be transformed. Their partners are leaving; their strategies are changing. And their stories are all marked by their common failure to combine early-stage biopharmaceutical venture capital with later-stay growth capital and buyouts into so-called "balanced funds."

You may also be interested in...



Clarus Bets Big: Eyes Big Investments, New Fund

Clarus Ventures, a year-and-a-half removed from raising its debut fund, likely will return for seconds later this year, and the firm is betting its new strategy for investing in medical device companies promises to produce returns that its limited partners will enjoy.

European Biotech Is Specialty Pharma

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.

Ex-Shire Team Builds New Euro-Specialty Group

Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel